Botulinum Toxin Market Size By Product (Botulinum Toxin A, Botulinum Toxin B), By Application (Medical, Aesthetic), By Gender (Female, Male), By Age Group (13-19, 20-29, 30-39, 40-54, 55 and Above), By End-use (Hospitals, Dermatology Clinics, Spas & Cosmetic Centers), COVID19 Impact Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027

Published Date: May 2021  |  Report ID: GMI3408  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 169   |   Base Year: 2020

Summary Table of Contents Industry Coverage Methodology

Industry trends

Botulinum Toxin Market size exceeded USD 3.5 billion in 2020 and is poised to grow at over 5.9% CAGR between 2021 to 2027. Increasing aesthetic consciousness amongst individuals coupled with rising number of non-invasive cosmetic procedures worldwide will boost the market growth.

Botulinum Toxin Market Overview

Get more details on this report - Request Free Sample PDF

Botulinum toxin is a neurotoxin protein produced by Clostridium botulinum, a gram-positive anaerobic bacterium. Botulinum toxin prevents the release of the neurotransmitter acetylcholine from axon ending at the neuromuscular junction. The botulinum toxin is used to treat certain eye disorders and to reduce the cosmetic appearance of wrinkles. Also, botulinum toxin is a non-invasive cosmetic procedure in nature. This has increased its usage in several aesthetic procedures over the recent years and propelled the industry growth.

The spread of COVID-19 pandemic across the globe has impacted the botulinum toxin market negatively in 2020. Various companies witnessed a dip ranging from 9% to 30% in the sales of botulinum toxin products in 2020 due to the COVID-19 pandemic. This is attributed to increasing number of COVID-19 infections along with nationwide lockdowns and delaying or postponing of the non-essential surgical and non-invasive procedures.

These procedures are not considered critical or life-saving procedure and hence, come under elective surgical procedures. Several countries across the globe have restructured the healthcare system and re-prioritized the surgical procedures. Thus, owing to such aspects, there was decrease in the number of aesthetic procedures, thereby negatively impacting the market in 2020. Additionally, with consecutive second and third wave of COVID-19 infections across various countries, the market will observe sluggish growth up till 2022.

Availability of minimally invasive surgeries will offer growth opportunities

Large percentage of population including people aged above 40 years are focusing on the physical appearance and wish to remain young-looking. Thus, growing emphasis on aesthetic features by women, especially in developed countries will stimulate the market expansion. Also, botulinum toxin is used to treat several age-related conditions such as forehead lines, glabellar lines, crow’s feet and others. Hence, people above the age of 40 are prone to such signs of ageing. Thus, botulinum toxin procedures are gaining more importance among the population aged between 40-54 years, thereby augmenting the market value. Furthermore, botulinum toxin treatment for skin rejuvenation is non-invasive alternative to surgical procedures that will further favor product demand.

High cost of botulinum toxin procedures may slow down the market demand

Cost-intensive nature of botulinum toxin surgeries may hinder the demand for such procedures over the forecast timeframe. The average cost of botulinum toxin injection in the U.S. is around USD 397 which is further associated with surgeon’s fee. Also, the cost of botulinum toxin injections depends on few factors such as how advanced the wrinkles and fine lines are, or how quickly people want to treat the areas of concern. Moreover, the botulinum toxin surgery is not a permanent procedure and requires frequently or repeated treatments that include additional costs. Thus, overall high procedural cost of botulinum toxin may hamper the market size. Low affordability of these procedures in the lower income group from emerging countries may restrict the industry expansion.

Botulinum toxin A has greater efficacy and safer in long lasting results that will foster the segment growth

The botulinum toxin A segment accounted for USD 3.4 billion in 2020. Growing application in aesthetic and medical field along with the rise in interest of manufacturers to develop such products will impel the market progression. Various botulinum toxin A products are commercially available in the market that include Dysport and Botox. These products have been clinically proven to be effective and safe in long terms with minimal side effects, thus increasing the product demand and subsequently driving the industry value.

High consciousness amongst individuals regarding their aesthetic appearance will influence the botulinum toxin market revenue

The aesthetic application segment will showcase a 5.2% growth rate through 2027. Increasing awareness regarding cosmetic procedures to reduce signs of ageing, particularly in women has stimulated the demand for botulinum toxin. Additionally, the predominance use of botulinum toxin in aesthetic procedures will drive the segment expansion. An increase in concern of people regarding their appearance in developed and developing regions will further increase the number of cosmetic surgeries, thereby fostering the market growth.

Rising trends in females for skin rejuvenation at middle-age and increasing number of aesthetic surgeries will spur the segment value

Female segment dominated more than 93.2% of the botulinum toxin market share in 2020 due to growing trends in females for skin rejuvenation at middle-age coupled with increasing number of aesthetic surgeries. For instance, according to the Aesthetic Society report, nearly 651,360 (38%) females aged between 35-50 years underwent botulinum toxin surgery in 2019. Also, females of this age group show signs of ageing such as forehead lines, frown lines and crow’s feet among others. Thus, with the help of botulinum toxin products such signs can be reduced, thereby supplementing the market expansion.

Growing application of botulinum toxin to reduce signs of ageing has increased the acceptance rate of botulinum toxin in 40-54 age group segment

Botulinum Toxin Market Size

Get more details on this report - Request Free Sample PDF

The age group between 40-54 years is estimated to attain a CAGR of 5.9% by 2027 on account of rising application of botulinum toxin to reduce signs of ageing. For instance, the age group populations between 40-54 years are prone to ageing signs such as frown lines, crow’s feet and forehead lines. Therefore, they opt for botulinum toxin procedures to reduce such ageing signs. This will increase the product demand and spur the segment revenue. Furthermore, increasing disposable income and rising awareness regarding aesthetic procedures will further propel the industry progression.

High demand for surgeries that are being performed in dermatological clinics will upsurge the market value

Dermatology clinics segment in the botulinum toxin market is predicted to reach USD 2.8 billion by 2027 owing to increasing number of dermatological clinics, high patient preference towards this type of setting for cosmetic procedure and state-of-art facility. Also, high demand for surgeries that are being performed in dermatological clinics will upsurge the industry demand. Increasing prevalence of cervical dystonia will boost the demand for minimally invasive treatments that are being performed in the dermatological clinics, thereby driving the industry growth.

High disposable income along with increasing number of aesthetic procedures across the North America region will augment the market revenue

Global Botulinum Toxin Market

Get more details on this report - Request Free Sample PDF

North America botulinum toxin market size will exceed USD 4.4 billion by 2027 due to availability of variety of aesthetic procedures along with growing disposable income. Also, in U.S., there has been rapid advancements in medical and aesthetic procedures over the last few years. The advanced technologies have introduced a wide range of solutions and products to patients seeking medical assistance.

Adoption of inorganic growth strategies to create a global footprint will pave growth opportunities for companies operating in the market

Prominent players operating in the market include AbbVie Inc (Allergan), Merz Pharma, Eisai Co., Ltd., Hugel Inc., Medytox Inc., Ipsen and Revance Therapeutics, Inc. These companies opt for various strategies such as partnerships, collaborations, mergers and acquisitions to create a global footprint and market competition.

Some of the recent industry developments:

  • In December 2020, Merz Therapeutics announced the U.S. FDA approval for its botulinum toxic product Xeomin to treat patients aged 2 years and older with chronic sialorrhea, or drooling. This approval Will enable the company to expand its customer base and strengthen its revenue generation stream.
  • In May 2020, AbbVie completed the acquisition of Allergan for its business expansion. This acquisition is expected to offer competitive edge to the company with Allergan’s leading aesthetic brands in the market.

The botulinum toxin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Product

  • Botulinum toxin A
  • Botulinum toxin B

Market, By Application

  • Medical
  • Aesthetic

Market, By Gender

  • Female
  • Male

Market, By Age Group

  • 13-19
  • 20-29
  • 30-39
  • 40-54
  • 55 and above

Market, By End-use

  • Hospitals
  • Dermatology Clinics
  • Spas & cosmetic centers

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Turkey
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Egypt
    • Saudi Arabia


Frequently Asked Questions (FAQ) :

Botulinum toxin market share surpassed USD 3.5 billion in 2020 and will expand at a CAGR of 5.9% from 2021 to 2027.
Botulinum toxin A market recorded a revenue of USD 3.4 billion in 2020 and will depict appreciable growth owing to surging application in the aesthetic and medical industries.
The share of aesthetic applications will grow at a rate of 5.2% between 2021 and 2027 due to rising awareness regarding cosmetic procedures for reducing signs of ageing.
Botulinum toxin usage by people in the 40-54 years age group will witness a CAGR of 5.9% from 2021 to 2027, impelled by the increasing product application for decreasing signs of ageing.

Premium Report Details

  • Published Date: May 2021
  • Pages: 169
  • Tables: 285
  • Charts / Figures: 20
  • Companies covered: 12
  • Countries covered: 18

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X